Physician profile
Eric S Davidson
NPI 1669437513
$2,201.58
in general payments reported to CMS, 2019-2025
25 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $179 · 2021: $447 · 2022: $236 · 2023: $90.81 · 2024: $293 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $334.33 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $286.83 | 2019-2025 | |
| Amgen INC. | $241.48 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $173.95 | 2019-2025 | Farxiga |
| Pfizer INC. | $124.20 | 2019-2025 | |
| Esperion Therapeutics, INC. | $108.73 | 2021-2023 | Nexletol |
| Lantheus Medical Imaging, INC. | $105.41 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.48 | 2019-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $77.16 | 2021-2025 | Onpattro |
| Amarin Pharma, INC. | $75.56 | 2019-2020 | |
| Boston Scientific Corporation | $69.01 | 2025 | Acuity Steerable |
| Regeneron Healthcare Solutions, INC. | $68.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.25 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $55.38 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $52.74 | 2021-2025 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $37.75 | 2024 | |
| Abiomed | $33.33 | 2024 | Impella |
| Medtronic, INC. | $33.31 | 2024 | Linq II |
| Kiniksa Pharmaceuticals, Ltd. | $31.92 | 2021 | |
| Terumo Medical Corporation | $25.04 | 2019-2024 | Glidewire |
| Chiesi USA, INC. | $24.70 | 2019-2020 | |
| Philips North America LLC | $22.49 | 2021 | |
| Novo Nordisk INC | $21.99 | 2022 | |
| Eisai INC. | $21.37 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.